Welcome to our dedicated page for Cannapharmarx news (Ticker: CPMD), a resource for investors and traders seeking the latest updates and insights on Cannapharmarx stock.
CannaPharmaRX, Inc. reports developments in cannabis cultivation and international export operations. The company operates cannabis production activities in Alberta and has described shipments, purchase orders, harvest activity and distribution relationships tied to medical cannabis markets including Israel and Germany.
Recurring updates for CPMD include facility utilization, cannabis strain development, product quality and THC-related pricing, inventory preparation, export licensing, quarterly financial results and balance-sheet initiatives. Company news also covers Canadian regulatory matters, including continuous-disclosure issues with the British Columbia Securities Commission.
CannapharmaRx, Inc. (OTC PINK:CPMD) announced the sale of its Hanover, Ontario facility for $2,000,000 CAD. The facility spans ten acres with 48,800 square feet of growing space. The decision to sell was made by senior management to focus on acquiring a more advanced facility in Cremona, Alberta, which will enhance production capabilities, enabling the company to produce 5,200 kilograms of cannabis annually. The transaction is set to close on June 30, 2021, improving the company's balance sheet and reducing certain liabilities.
CannapharmaRx, Inc. (OTC PINK: CPMD) recently announced a restructuring of its Board of Directors, effective March 12, 2021, with Jim Samuelson and Matt Nicosia resigning to focus on other business obligations. Their departures were not due to disagreements with the company. CEO Nick Colvin expressed gratitude for their contributions as CannapharmaRx prepares for significant asset acquisitions in Saskatchewan and Alberta, expected to close in April 2021. The company aims to enhance its position in high-technology cannabis production and has a 48,500 square foot grow facility under development.
CannapharmaRx, Inc. (OTC PINK:CPMD) announced a strategic partnership with Klonetics Plant Science, Inc. on September 30, 2020. This collaboration will utilize CannapharmaRx's business expertise to support Klonetics' projects in genetic acquisition and cannabis cultivation. CannapharmaRx will also acquire a minority stake in Klonetics, granting them exclusivity to certain intellectual properties, potentially enhancing their market competitiveness. CannapharmaRx is developing a 48,500 square foot cannabis facility and plans to list its shares on the Canadian Stock Exchange.
CannaPharmaRx (OTC PINK:CPMD) announced the full repayment of its short-term convertible debt due in Q3 2020, enhancing its financial position. The company previously secured $3 million financing from Triton Funds, which is contingent on SEC Form S-1 approval. This funding aims to support the acquisition and development of cannabis facilities, focusing on genetics and cultivation. CannaPharmaRx is also advancing plans for its 48,500 square foot facility and pursuing potential acquisitions to become a leader in efficient cannabis production in Canada.
CannaPharmaRx, Inc. (CPMD) reported its second quarter 2020 financial results, remaining a non-revenue generating entity. As of June 30, 2020, it had $3,789 in cash, up from $1,547 at the end of 2019, attributed to loans from its CEO and director. Operating expenses rose to $787,484, resulting in a net loss of $1,472,479 compared to $748,079 in Q2 2019. The company's focus remains on acquisitions, particularly the GN Ventures project, which has a cultivation capacity of 12,500 kg. CannaPharmaRx plans to list on the Canadian Stock Exchange in Q3 2020.
CannaPharmaRx (OTC PINK:CPMD) has secured a $3 million investment from Triton Funds, enhancing its capacity for cannabis production in California and Canada. CEO Nick Colvin highlighted the partnership's potential to accelerate the company's growth in the cannabis industry.
The company owns a 48,500 square foot cannabis facility under development and aims to become a leader in high-quality, low-cost cannabis production. CannaPharmaRx is also preparing for listings on the Canadian Stock Exchange and OTCQB.